1. A215 EVALUATING THE COMPARABILITY OF CARE FOR PERSONS ADMITTED TO TORONTO AREA HOSPITALS WITH ACUTE SEVERE ULCERATIVE COLITIS. (7th March 2023) Authors: Vukovic, S; You, X; Roberts, S; Razak, F; Verma, A; Targownik, L Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 6(2023)Supplement 1 Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atmospheric monitoring strategy for the Ali site, Tibet. (March 2015) Authors: Yao, Y; Zhou, Y; Liu, L; Wang, H; Yin, J; You, X; Fu, X Journal: Journal of physics Issue: Number 595 (2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients. (August 2014) Authors: Zhang, J; Dou, Y; Zhong, Z; Su, J; Xu, D; Tang, F; Zhang, X; Zhao, Y; Zeng, X; Zhang, F; You, X Journal: Lupus Issue: Volume 23:Number 9(2014) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis. (April 2016) Authors: Fisher, E; Nakamura, K; Lee, J-C; You, X; Sperling, B; Rudick, RA Journal: Multiple sclerosis Issue: Volume 22:Number 5(2016) Page Start: 668 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Mycoplasma pneumoniae lipids license TLR-4 for activation of NLRP3 inflammasome and autophagy to evoke a proinflammatory response. (29th September 2020) Authors: Luo, H; He, J; Qin, L; Chen, Y; Chen, L; Li, R; Zeng, Y; Zhu, C; You, X; Wu, Y Journal: Clinical and experimental immunology Issue: Volume 203:Number 1(2021) Page Start: 66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S67 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a phase 3 randomized, controlled trial (EXPAND). (December 2018) Authors: Chuang, C-C; Rizio, AA; Loop, B; Lekstrom-Himes, J; You, X; Kosinski, M; Rendas-Baum, R; Davies, JC; Rowe, SM; Yang, Y Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE). (December 2018) Authors: Yang, Y; Rizio, AA; Chuang, C-C; Loop, B; You, X; Kosinski, M; Rendas-Baum, R; Lekstrom-Himes, J; Taylor-Cousar, J; Sole, A; Elborn, JS Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. (April 2015) Authors: Simon, JH; Kinkel, RP; Kollman, C; O'Connor, P; Fisher, E; You, X; Hyde, R Journal: Multiple sclerosis Issue: Volume 21:Number 4(2015) Page Start: 415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗